Inmune Bio (INMB) Long-Term Deferred Tax (2019 - 2024)
Inmune Bio (INMB) posted Long-Term Deferred Tax of $25.7 million for Q4 2024, up 4615.6% sequentially from $545000.0 in Q3 2024, and up 31.12% YoY from $19.6 million in Q1 2024.
Inmune Bio (INMB) Long-Term Deferred Tax (2019 - 2024) Analysis & Trends
Inmune Bio has reported Long-Term Deferred Tax for 6 years, with the latest figure at $25.7 million in Q4 2024.
- Quarterly Long-Term Deferred Tax rose 31.12% year-over-year to $25.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $25.7 million (up 31.12% YoY) and the FY2024 annual result came in at $25.7 million, up 31.12% from the prior year.
- Long-Term Deferred Tax climbed to $25.7 million in Q4 2024 per INMB's latest filing, from $545000.0 in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $25.7 million in Q4 2024 and troughed at $545000.0 in Q3 2024.
- A 5-year average of $8.3 million and a median of $3.7 million in 2021 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2020 and 2023: Long-Term Deferred Tax increased 15.4% in 2020, then surged 260.23% in 2023.
- Over 5 years, Long-Term Deferred Tax stood at $2.2 million in 2020, then jumped by 68.12% to $3.7 million in 2021, then surged by 46.97% to $5.4 million in 2022, then soared by 260.23% to $19.6 million in 2023, then soared by 31.12% to $25.7 million in 2024.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $25.7 million, $545000.0, and $590000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 25.70 Mn |
| Sep 30, 2024 | 545,000.00 |
| Jun 30, 2024 | 590,000.00 |
| Dec 31, 2023 | 19.60 Mn |
| Dec 31, 2022 | 5.44 Mn |
| Dec 31, 2021 | 3.70 Mn |
| Dec 31, 2020 | 2.20 Mn |
| Dec 31, 2019 | 1.91 Mn |